Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Ginkgo Bioworks Holdings Inc (NYSE: DNA) was $8.09 for the day, up 5.06% from the previous closing price of $7.70. In other words, the price has increased by $5.06 from its previous closing price. On the day, 0.72 million shares were traded. DNA stock price reached its highest trading level at $8.2 during the session, while it also had its lowest trading level at $7.73.
Ratios:
Our analysis of DNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.71 and its Current Ratio is at 4.71. In the meantime, Its Debt-to-Equity ratio is 0.54 whereas as Long-Term Debt/Eq ratio is at 0.54.
Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 27 ’24 when Che Austin bought 99 shares for $7.86 per share.
Che Austin bought 99 shares of DNA for $792 on Sep 26 ’24. On Sep 25 ’24, another insider, Che Austin, who serves as the Officer of the company, bought 99 shares for $8.02 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 449604992 and an Enterprise Value of 142322560. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.31 while its Price-to-Book (P/B) ratio in mrq is 0.48. Its current Enterprise Value per Revenue stands at 0.772 whereas that against EBITDA is -0.225.
Stock Price History:
Over the past 52 weeks, DNA has reached a high of $82.80, while it has fallen to a 52-week low of $5.26. The 50-Day Moving Average of the stock is -13.52%, while the 200-Day Moving Average is calculated to be -75.41%.
Shares Statistics:
DNA traded an average of 1.66M shares per day over the past three months and 2104550 shares per day over the past ten days. A total of 38.13M shares are outstanding, with a floating share count of 35.44M. Insiders hold about 32.59% of the company’s shares, while institutions hold 42.96% stake in the company. Shares short for DNA as of 1726185600 were 6345269 with a Short Ratio of 3.81, compared to 1723680000 on 3835556. Therefore, it implies a Short% of Shares Outstanding of 6345269 and a Short% of Float of 20.34.
